3D QSAR studies of the interaction between β-tubulin and microtubule stabilizing antimitotic agents (MSAA). A combined pharmacophore generation and pseudoreceptor modeling approach applied to taxanes and epothilones

Farmaco

Volumn 58, Issue 5, 2003, Pages 357-361

  Manetti, Fabrizio ^a   Forli, Stefano ^a   Maccari, Laura ^a   Corelli, Federico ^a   Botta, Maurizio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

3D QSAR; Epothilones; Pseudoreceptor modeling; Taxanes; Tubulin

Indexed keywords

ANTIMITOTIC AGENT; BETA TUBULIN; EPOTHILONE DERIVATIVE; TAXANE DERIVATIVE;

ARTICLE; BINDING SITE; DRUG ISOLATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; EXPERIMENTAL MODEL; PHARMACOPHORE; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 0037407830     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(03)00052-1     Document Type: Article

References (34)

1. Slichenmyer W.J., Von Hoff D.D. Taxol: a new and effective anticancer drug. Anticancer Drugs. 2:1991;3519-3530.
2. Chaudhry V., Rowinsky E.K., Sartorius S.E., Donehower R.C., Cornblath D.R. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann. Neurol. 35:1994;304-311.
3. Schrijvers D., Wanders J., Dirix L., Prove A., Vonck I., Van Oosterom A., Kaye S. Coping with toxicities of docetaxel (taxotere). Ann. Oncol. 4:1993;610-611.
4. Bollag D.M., McQueney P.A., Zhu J., Hensens O., Koupal L., Liesch J., Goetz M., Lazarides E., Woods C.M. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55:1995;2325-2333.
5. Chou T.C., O'Conner O.A., Tong W.P., Guan Y., Zhang Z.G., Stachel S.J., Lee C., Danishefsky S.J. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc. Natl. Acad. Sci. USA. 98:2001;8113-8118.
6. Stachel S.J., Biswas K., Danishefsky S.J. The epothilones, eleutherobins, and related types of molecules. Curr. Pharm. Des. 7:2001;1277-1290.
7. Lavelle F. New taxanes and epothilone derivatives in clinical trials. Bull. Cancer. 89:2002;343-350.
8. Kindler H.L., Shulman K.L. Metastatic colorectal cancer. Curr. Treat. Opt. Oncol. 2:2001;459-471.
9. Colevas A.D., West P.J., Cheson B.D. Clinical trials referral resource. Current clinical trials of epothilone B analogue (BMS-247550). Oncology. 15:2001;1168-1169.
10. Seiden M.V. Ovarian cancer. Oncologist. 6:2001;327-332.
11. Blagosklonny M.V. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia. 15:2001;936-941.
12. Several examples of clinical protocols are reported at http://clinicalstudies.info.nih.gov.
13. Lowe J., Li H., Downing K.H., Nogales E. Refined structure of αβ-tubulin at 3.5 Å resolution. J. Mol. Biol. 313:2001;1045-1057.
14. Winkler J., Axelson P.H. A model for the taxol (paclitaxel)/epothilone pharmacophore. Bioorg. Med. Chem. Lett. 6:1996;2963-2966.
15. Ojima I., Chakravarty S., Inoue T., Lin S., He L., Horwitz S.B., Kuduk S.D., Danishefsky S.J. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc. Natl. Acad. Sci. USA. 96:1999;4256-4261.
16. Giannakakou P., Gussio R., Nogales E., Downing K.H., Zaharevitz D., Bollbuck B., Poy G., Sachett D., Nicolaou K.C., Fojo T. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. USA. 97:2000;2904-2909.
17. He L., Jagtap P.G., Kingston D.G.I., Shen H.-J., Orr G.A., Horwitz S.B. A common pharmacophore for taxol and the epothilones based on the biological activity of a taxane molecule lacking a C-13 side chain. Biochemistry. 39:2000;3972-3978.
18. Lee K.W., Briggs J.M. Comparative molecular field analysis (CoMFA) study of epothilones-tubulin depolymerization inhibitors: pharmacophore development using 3D QSAR methods. J. Comput. Aid. Mol. Des. 15:2001;41-55.
19. Wang M., Xia X., Kim Y., Hwang D., Jansen J.H., Botta M., Liotta D.C., Snyder J.P. A unified and quantitative receptor model for the microtubule binding of paclitaxel and epothilone. Org. Lett. 1:1999;43-46.
20. L. Maccari, F. Manetti, F. Corelli, M. Botta, 3D QSAR studies of the interaction between β-tubulin and microtubules stabilizing antimitotic agents (MSAA). 1. A pseudoreceptor model for taxanes based on the experimental structure of tubulin, Il Farmaco, submitted for publication.
21. Catalyst, version 4.6, Accelrys, Inc., 9685 Scranton Road, San Diego, CA.
22. Wang M., Cornett B., Nettles J., Liotta D.C., Snyder J.P. The oxetane ring in taxol. J. Org. Chem. 65:2000;1059-1068.
23. Guéritte F. General and recent aspects of the chemistry and structure-activity relationships of taxoids. Curr. Pharm. Des. 7:2001;1229-1249.
24. Barboni L., Datta A., Dutta D., Georg G.I., Vander Velde D.G., Himes R.H., Wang M., Snyder J.P. Novel D-seco paclitaxel analogues: synthesis, biological evaluation, and model testing. J. Org. Chem. 66:2001;3321-3329.
25. Gueritte-Voegelein F., Guenard D., Lavell F., LeGoff M.T., Mangatal L., Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J. Med. Chem. 34:1991;992-998.
26. Swindell C.S., Krauss N.E., Horwitz S.B., Ringel I. Biologically active taxol analogues with deleted A-ring side chain substituents and variable C-2′ configurations. J. Med. Chem. 34:1991;1176-1184.
27. Appendino G., Danieli B., Jakupovic J., Belloro E., Scambia G., Bombardelli E. Synthesis and evaluation of C-seco paclitaxel analogues. Tetrahedron Lett. 38:1997;4273-4276.
28. Gurrath M., Muller G., Holtje H.D. Perspective in Drug Discovery Today. 12/13/14:1998;155-157.
29. PrGen, version 2.1.1, Biographics Laboratory, Basel, Switzerland.
30. Zbinden P., Dobler M., Folkers G., Vedani A. PrGen: pseudoreceptor modeling using receptor-mediated ligand alignment and pharmacophore equilibration. Quant. Struct.-Act. Relat. 17:1998;122-130.
31. The correlation coefficient of 0.81 and the root mean square deviation of 0.85 indicated a good agreement between experimental and calculated free energy of ligand binding.
32. Nicolaou K.C., Scarpelli R., Bollbuck B., Werschkun B., Pereira M.M.A., Wartmann M., Altmann K.-H., Zaharevitz D., Gussio R., Giannakakou P. Chemical synthesis and biological properties of pyridine epothilones. Chem. Biol. 7:2000;593-599.
33. Nicolaou K.C., Vourloumis D., Li T., Pastor J., Winssinger N., Je T., Ninkovic S., Sarabia F., Vallberg H., Roschangar F., King P.N., Finlay M.R.V., Giannakakou P., Verdier-Pinard P., Hamel E. Designed epothilones: solid phase synthesis on microtubes, tubulin assembly properties, and cytotoxic action against taxol-resistant tumor cells. Angew. Chem. Int. Ed. Engl. 36:1997;2097-2103.
34. Nicolaou K.C., Roschangar F., Vourloumis D. Chemical biology of epothilones. Angew. Chem. Int. Ed. Engl. 37:1998;2014-2045.